EasySep™小鼠TIL（CD45）正选试剂盒
产品号 #02697_C
用于扩增人造血细胞的无血清培养添加物
若您需要咨询产品或有任何技术问题，请通过官方电话 400 885 9050 或邮箱 info.cn@stemcell.com 与我们联系。
总览
StemSpan™ CC110含有多种早期作用的重组人（rh）细胞因子，旨在支持人造血细胞的扩增。该产品以100X浓缩液的形式提供。当添加到无血清培养基中时，StemSpan™ CC110可促进从人脐带血和骨髓中分离的CD34+细胞的扩增。StemSpan™ CC110刺激CD34+ 细胞的扩增效果与StemSpan™ CC100类似，但具有更高的纯度，适用于短期培养以激活干细胞和未成熟祖细胞的循环，而不一定促进后期祖细胞的增殖和分化。我们建议将StemSpan™ CC110与以下任意StemSpan™培养基搭配使用：•StemSpan™ SFEM（产品号 #09600）•StemSpan™ SFEM II（产品号 #09605）•StemSpan™-XF（产品号 #100-0073）•StemSpan™-AOF（产品号 #100-0130）
包含
• 重组人FMS样酪氨酸激酶3配体（Flt3L）
• 重组人干细胞因子（SCF）
• 重组人血小板生成素（TPO）
分类
添加剂
细胞类型
造血干/祖细胞
种属
人
应用
细胞培养，扩增
品牌
StemSpan
研究领域
药物发现和毒性检测，干细胞生物学，移植研究
制剂类别
无血清
产品说明书及文档
请在《产品说明书》中查找相关支持信息和使用说明，或浏览下方更多实验方案。
应用领域
本产品专为以下研究领域设计，适用于工作流程中的高亮阶段。探索这些工作流程，了解更多我们为各研究领域提供的其他配套产品。
相关材料与文献
技术资料 (6)
文献 (13)
Long-term erythropoiesis from constant numbers of CD34+ cells in serum-free cultures initiated with highly purified progenitor cells from human bone marrow.
The Journal of experimental medicine 1992 JUN
Abstract
To directly study the biological properties of purified hematopoietic colony-forming cell precursors,cells with a CD34+ CD45RAlo CD71lo phenotype were purified from human bone marrow using density separation and fluorescence-activated cell sorting,and were cultured in serum-free culture medium supplemented with various cytokines. In the presence of interleukin 3 (IL-3),IL-6,erythropoietin,and mast cell growth factor (a c-kit ligand),cell numbers increased approximately 10(6)-fold over a period of 4 wk,and the percentage of cells that expressed transferrin receptors (CD71) increased from less than 0.1% at day 0 to greater than 99% at day 14. Interestingly,the absolute number of CD34+ CD71lo cells did not change during culture. When CD34+ CD71lo cells were sorted from expanded cultures and recultured,extensive cell production was repeated,again without significant changes in the absolute number of cells with the CD34+ CD71lo phenotype that were used to initiate the (sub)cultures. These results document that primitive hematopoietic cells can generate progeny without an apparent decrease in the size of a precursor cell pool.
Intracoronary infusion of CD133+ and CD133-CD34+ selected autologous bone marrow progenitor cells in patients with chronic ischemic cardiomyopathy: cell isolation, adherence to the infarcted area, and body distribution.
Stem cells (Dayton,Ohio) 2006 OCT
Abstract
Central issues in intracoronary infusion (ICI) of bone marrow (BM)-cells to damaged myocardium for improving cardiac function are the cell number that is feasible and safe to be administrated as well as the retention of cells in the target area. Our study addressed these issues in eight patients with chronic ischemic cardiomyopathy undergoing ICI of selected BM-progenitors. We could immunomagnetically isolate 0.8 +/- 0.32 x 10(7) CD133(+) cells and 0.75 +/- 0.24 x 10(7) CD133(-)CD34(+) cells from 310 +/- 40 ml BM. After labeling these cells with (99m)Tc-hexamethylpropylenamineoxime,they were infused into the infarct-related artery without any complication. Scintigraphic images 1 (eight patients) and 24 hours (four patients) after ICI revealed an uptake of 9.2% +/- 3.6 and 6.8% +/- 2.4 of the total infused radioactivity in the infarcted area of the heart,respectively; the remaining activity was distributed mainly to liver and spleen. We conclude that through ICI of CD133(+) and CD133(-)CD34(+) BM-progenitors a significant number of them are preferentially attracted to and retained in the chronic ischemic myocardium.
In vitro expanded cells contributing to rapid severe combined immunodeficient repopulation activity are CD34+38-33+90+45RA-.
Stem cells (Dayton,Ohio) 2007 JAN
Abstract
Expansion of hematopoietic stem cells could be used clinically to shorten the prolonged aplastic phase after umbilical cord blood (UCB) transplantation. In this report,we investigated rapid severe combined immunodeficient (SCID) repopulating activity (rSRA) 2 weeks after transplantation of CD34(+) UCB cells cultured with serum on MS5 stromal cells and in serum- and stroma-free cultures. Various subpopulations obtained after culture were studied for rSRA. CD34(+) expansion cultures resulted in vast expansion of CD45(+) and CD34(+) cells. Independent of the culture method,only the CD34(+)33(+)38(-) fraction of the cultured cells contained rSRA. Subsequently,we subfractionated the CD34(+)38(-) fraction using stem cell markers CD45RA and CD90. In vitro differentiation cultures showed CD34(+) expansion in both CD45RA(-) and CD90(+) cultures,whereas little increase in CD34(+) cells was observed in both CD45RA(+) and CD90(-) cultures. By four-color flow cytometry,we could demonstrate that CD34(+)38(-)45RA(-) and CD34(+)38(-)90(+) cell populations were largely overlapping. Both populations were able to reconstitute SCID/nonobese diabetic mice at 2 weeks,indicating that these cells contained rSRA activity. In contrast,CD34(+)38(-)45RA(+) or CD34(+)38(-)90(-) cells contributed only marginally to rSRA. Similar results were obtained when cells were injected intrafemorally,suggesting that the lack of reconstitution was not due to homing defects. In conclusion,we show that after in vitro expansion,rSRA is mediated by CD34(+)38(-)90(+)45RA(-) cells. All other cell fractions have limited reconstitutive potential,mainly because the cells have lost stem cell activity rather than because of homing defects. These findings can be used clinically to assess the rSRA of cultured stem cells.
更多信息
| 物种 | 人 |
|---|---|
| Contains | • Recombinant human fms-like tyrosine kinase 3 ligand (Flt3L) • Recombinant human stem cell factor (SCF) • Recombinant human thrombopoietin (TPO) |
| 配方 | 无血清 |
相关产品
-
StemSpan™ CD34+扩增添加物 (10X)用于扩增人CD34+造血细胞的无血清培养添加物
-
StemSpan™ SFEM用于培养和扩增造血细胞的无血清培养基
-
StemSpan™ SFEM II用于培养和扩增造血细胞的无血清培养基
沪公网安备31010102008431号
在线联系